{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:57:25Z","timestamp":1793044645131,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>TIA-1 (T-cell intracellular antigen 1) is an RNA-binding protein central to the formation of stress granules (SGs) and modulation of inflammatory responses. Recent research has identified TIA-1 as a key player in neurodegenerative diseases, especially those involving Tau pathology such as in Alzheimer\u2019s disease (AD), in a subtype-dependent manner. Disease-modifying therapies for AD and related dementias are emerging, but their effectiveness hinges on timely and accurate diagnosis. This underscores urgent need for easily accessible and reliable blood biomarkers for early detection, disease monitoring, and subtype differentiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Accordingly, in this pilot study, we evaluated the plasma TIA-1 levels in healthy controls and across spectrum of neurodegenerative diseases to assess its clinical and biological significance. Plasma TIA-1 concentrations were measured in Alzheimer\u2019s disease, mild cognitive impairment due to AD (MCI-AD), vascular cognitive impairment (VCI), and other neurodegenerative diseases (NDs: synucleinopathies and tauopathies), and compared to healthy controls. Receiver operating characteristic (ROC) analyses and correlation studies with established biomarkers and cognitive scores were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Plasma TIA-1 levels were significantly reduced in AD, MCI-AD, VCI, and non-AD neurodegenerative diseases (synucleinopathies and tauopathies) compared to healthy controls, with the greatest reductions observed in non-AD neurodegenerative diseases. Strikingly, combined measurement of plasma TIA-1 and glial fibrillary acidic protein (GFAP) improved differentiation of AD subtypes, particularly distinguishing rpAD from non-rpAD cases. Plasma TIA-1 levels correlated with key biomarkers of neurodegeneration (p-Tau, A\u03b242, NFL) and cognitive decline, especially in early AD (MCI-AD). Notably, plasma TIA-1 mirrored the discriminatory patterns of CSF t-Tau and p-Tau, distinguishing non-AD neurodegenerative diseases from specifically rpAD subtype, indicating that plasma TIA-1 captures the same underlying pathophysiological processes as the \u201cgold standard\u201d CSF markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma TIA-1 is a promising biomarker candidate for neurodegenerative diseases, with alterations that reflect disease presence and severity. In this pilot cohort, its combination with GFAP noticeably improved discrimination between AD subtypes, supporting its potential added value in composite biomarker approaches. Given its accessibility, TIA-1 is a strong candidate for further evaluation as part of future blood-based biomarker panels, although it\u2019s clinical utility still needs confirmation in larger, independent studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-02020-9","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:05:41Z","timestamp":1774404341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reduced plasma TIA-1: bridging established pathology and novel biomarker potential"],"prefix":"10.1186","volume":"18","author":[{"given":"Neelam","family":"Younas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrar","family":"Younas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Camila Fernandez","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Dittmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias J.","family":"Legler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyaba","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2020_CR1","doi-asserted-by":"publisher","unstructured":"Gilks N, Kedersha N, Ayodele M et al. Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol Biol Cell. Published online 2004. https:\/\/doi.org\/10.1091\/mbc.E04-08-0715","DOI":"10.1091\/mbc.E04-08-0715"},{"key":"2020_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06634-0","author":"LP Byres","year":"2021","unstructured":"Byres LP, Mufteev M, Yuki KE, et al. Identification of TIA1 mRNA targets during human neuronal development. Mol Biol Rep Published online. 2021. https:\/\/doi.org\/10.1007\/s11033-021-06634-0.","journal-title":"Mol Biol Rep Published online"},{"key":"2020_CR3","doi-asserted-by":"publisher","unstructured":"F\u00f6rch P, Valc\u00e1rcel J. Molecular mechanisms of gene expression regulation by the apoptosis-promoting protein TIA-1. Apoptosis. Published online 2001. https:\/\/doi.org\/10.1023\/A:1012441824719","DOI":"10.1023\/A:1012441824719"},{"key":"2020_CR4","doi-asserted-by":"publisher","unstructured":"Phillips K, Kedersha N, Shen L, Blacksheart PJ, Anderson P. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor \u03b1, cyclooxygenase 2, and inflammatory arthritis. Proc Natl Acad Sci U S A. Published online 2004. https:\/\/doi.org\/10.1073\/pnas.0400148101","DOI":"10.1073\/pnas.0400148101"},{"key":"2020_CR5","doi-asserted-by":"publisher","unstructured":"LeBlang CJ, Medalla M, Nicoletti NW et al. Reduction of the RNA Binding Protein TIA1 Exacerbates Neuroinflammation in Tauopathy. Front Neurosci. Published online 2020. https:\/\/doi.org\/10.3389\/fnins.2020.00285","DOI":"10.3389\/fnins.2020.00285"},{"key":"2020_CR6","doi-asserted-by":"publisher","unstructured":"Ash PEA, Lei S, Shattuck J et al. TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau. Proc Natl Acad Sci U S A. Published online 2021. https:\/\/doi.org\/10.1073\/pnas.2014188118","DOI":"10.1073\/pnas.2014188118"},{"key":"2020_CR7","doi-asserted-by":"publisher","unstructured":"Younas N, Zafar S, Shafiq M et al. SFPQ and Tau: critical factors contributing to rapid progression of Alzheimer\u2019s disease. Acta Neuropathol. Published online 2020. https:\/\/doi.org\/10.1007\/s00401-020-02178-y","DOI":"10.1007\/s00401-020-02178-y"},{"key":"2020_CR8","doi-asserted-by":"publisher","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol. Published online 2012. https:\/\/doi.org\/10.1097\/NEN.0b013e31824b211b","DOI":"10.1097\/NEN.0b013e31824b211b"},{"key":"2020_CR9","doi-asserted-by":"publisher","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. Published online 2021. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","DOI":"10.1038\/s41591-021-01382-x"},{"key":"2020_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13655","author":"P Wang","year":"2024","unstructured":"Wang P, Lynn A, Miskimen K, et al. Genome-wide association studies identify novel loci in rapidly progressive Alzheimer\u2019s disease. Alzheimer\u2019s Dement Published online. 2024. https:\/\/doi.org\/10.1002\/alz.13655.","journal-title":"Alzheimer\u2019s Dement Published online"},{"issue":"1","key":"2020_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-023-01249-y","volume":"15","author":"JM Herden","year":"2023","unstructured":"Herden JM, Hermann P, Schmidt I, et al. Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2023;15(1):1\u201312. https:\/\/doi.org\/10.1186\/s13195-023-01249-y.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"2020_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.189","author":"C Schmidt","year":"2011","unstructured":"Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive alzheimer disease. Arch Neurol Published online. 2011. https:\/\/doi.org\/10.1001\/archneurol.2011.189.","journal-title":"Arch Neurol Published online"},{"key":"2020_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/nature20814","author":"W Qiang","year":"2017","unstructured":"Qiang W, Yau WM, Lu JX, Collinge J, Tycko R. Structural variation in amyloid-\u03b2 fibrils from Alzheimer\u2019s disease clinical subtypes. Nature Published online. 2017. https:\/\/doi.org\/10.1038\/nature20814.","journal-title":"Nature Published online"},{"key":"2020_CR14","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180155","author":"JA Pillai","year":"2018","unstructured":"Pillai JA, Appleby BS, Safar J, Leverenz JB. Rapidly progressive Alzheimer\u2019s disease in two distinct autopsy cohorts. J Alzheimer\u2019s Dis Published online. 2018. https:\/\/doi.org\/10.3233\/JAD-180155.","journal-title":"J Alzheimer\u2019s Dis Published online"},{"issue":"17","key":"2020_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21176298","volume":"21","author":"P Podlesniy","year":"2020","unstructured":"Podlesniy P, Llorens F, Puigr\u00f2s M, et al. Cerebrospinal fluid mitochondrial DNA in rapid and slow progressive forms of Alzheimer\u2019s disease. Int J Mol Sci. 2020;21(17):1\u201314. https:\/\/doi.org\/10.3390\/ijms21176298.","journal-title":"Int J Mol Sci"},{"key":"2020_CR16","doi-asserted-by":"publisher","unstructured":"Kim C, Haldiman T, Kang SG et al. Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer\u2019s disease. Sci Transl Med. Published online 2022. https:\/\/doi.org\/10.1126\/scitranslmed.abg0253","DOI":"10.1126\/scitranslmed.abg0253"},{"key":"2020_CR17","doi-asserted-by":"publisher","unstructured":"Janelidze S, Teunissen CE, Zetterberg H et al. Head-to-Head Comparison of 8 Plasma Amyloid-\u03b2 42\/40 Assays in Alzheimer Disease. JAMA Neurol. Published online 2021. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3180","DOI":"10.1001\/jamaneurol.2021.3180"},{"key":"2020_CR18","doi-asserted-by":"publisher","unstructured":"Benedet AL, Brum WS, Hansson O et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer\u2019s Res Ther. Published online 2022. https:\/\/doi.org\/10.1186\/s13195-021-00942-0","DOI":"10.1186\/s13195-021-00942-0"},{"key":"2020_CR19","doi-asserted-by":"publisher","unstructured":"Vanderweyde T, Apicco DJ, Youmans-Kidder K et al. Interaction of tau with the RNA-Binding Protein TIA1 Regulates tau Pathophysiology and Toxicity. Cell Rep. Published online 2016. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.045","DOI":"10.1016\/j.celrep.2016.04.045"},{"key":"2020_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2013.07.004","author":"N Kedersha","year":"2013","unstructured":"Kedersha N, Ivanov P, Anderson P. Stress granules and cell signaling: More than just a passing phase? Trends Biochem Sci Published online. 2013. https:\/\/doi.org\/10.1016\/j.tibs.2013.07.004.","journal-title":"Trends Biochem Sci Published online"},{"key":"2020_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-019-0222-5","author":"B Wolozin","year":"2019","unstructured":"Wolozin B, Ivanov P. Stress granules and neurodegeneration. Nat Rev Neurosci Published online. 2019. https:\/\/doi.org\/10.1038\/s41583-019-0222-5.","journal-title":"Nat Rev Neurosci Published online"},{"key":"2020_CR22","doi-asserted-by":"publisher","unstructured":"Apicco DJ, Ash PEA, Maziuk B et al. Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat Neurosci. Published online 2018. https:\/\/doi.org\/10.1038\/s41593-017-0022-z","DOI":"10.1038\/s41593-017-0022-z"},{"key":"2020_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement Published online. 2011. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimer\u2019s Dement Published online"},{"key":"2020_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002923","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology Published online. 2016. https:\/\/doi.org\/10.1212\/WNL.0000000000002923.","journal-title":"Neurology Published online"},{"key":"2020_CR25","doi-asserted-by":"publisher","unstructured":"Skrobot OA, Black SE, Chen C et al. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer\u2019s Dement. Published online 2018. https:\/\/doi.org\/10.1016\/j.jalz.2017.09.007","DOI":"10.1016\/j.jalz.2017.09.007"},{"key":"2020_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00955-9","author":"P Hermann","year":"2022","unstructured":"Hermann P, Villar-Piqu\u00e9 A, Schmitz M, et al. Plasma Lipocalin 2 in Alzheimer\u2019s disease: potential utility in the differential diagnosis and relationship with other biomarkers. Alzheimer\u2019s Res Ther Published online. 2022. https:\/\/doi.org\/10.1186\/s13195-021-00955-9.","journal-title":"Alzheimer\u2019s Res Ther Published online"},{"key":"2020_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/bf03028618","author":"ME Soto","year":"2008","unstructured":"Soto ME, Andrieu S, Arbus C, et al. Rapid cognitive decline in Alzheimer\u2019s disease. Consensus paper. J Nutr Heal Aging Published online. 2008. https:\/\/doi.org\/10.1007\/bf03028618.","journal-title":"J Nutr Heal Aging Published online"},{"key":"2020_CR28","doi-asserted-by":"publisher","unstructured":"Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lle\u00f3 A. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Neurology. Published online 2023. https:\/\/doi.org\/10.1212\/WNL.0000000000207193.","DOI":"10.1212\/WNL.0000000000207193"},{"key":"2020_CR29","doi-asserted-by":"crossref","unstructured":"Webber CJ, van de Spek SJF, Cruz AL et al. TIA1 Mediates Divergent Inflammatory Responses to Tauopathy in Microglia and Macrophages. BioRxiv Prepr Serv Biol. Published online 2024.","DOI":"10.1101\/2024.11.06.622325"},{"key":"2020_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.15.4154","author":"M Piecyk","year":"2000","unstructured":"Piecyk M, Wax S, Beck ARP, et al. TIA-1 is a translational silencer that selectively regulates the expression of TNF-\u03b1. EMBO J Published online. 2000. https:\/\/doi.org\/10.1093\/emboj\/19.15.4154.","journal-title":"EMBO J Published online"},{"key":"2020_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880009","author":"S Lyle","year":"2000","unstructured":"Lyle S, Salhany KE, Elder DE. TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas. Mod Pathol Published online. 2000. https:\/\/doi.org\/10.1038\/modpathol.3880009.","journal-title":"Mod Pathol Published online"},{"key":"2020_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2023.100062","author":"M Luebke","year":"2023","unstructured":"Luebke M, Parulekar M, Thomas FP. Fluid biomarkers for the diagnosis of neurodegenerative diseases. Biomarkers Neuropsychiatry Published online. 2023. https:\/\/doi.org\/10.1016\/j.bionps.2023.100062.","journal-title":"Biomarkers Neuropsychiatry Published online"},{"key":"2020_CR33","doi-asserted-by":"publisher","unstructured":"Cruz A, Verma M, Wolozin B. The Pathophysiology of Tau and Stress Granules in Disease. In: Advances in Experimental Medicine and Biology.; 2019. https:\/\/doi.org\/10.1007\/978-981-32-9358-8_26","DOI":"10.1007\/978-981-32-9358-8_26"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02020-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02020-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02020-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:48:19Z","timestamp":1781642899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02020-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2020"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02020-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human subjects provided informed consent. Details are described in methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}